Isosceles Pharmaceuticals

Early Stage

Helping Solve America's Opioid Crisis

Overview

Raised to Date: Raised: $4,783,551

Total Commitments ($USD)

Platform

Equifund CFP

Start Date

10/04/2022

Close Date

10/02/2023

Min. Goal

$20,000

Max. Goal

$5,000,000

Min. Investment

$500

Security Type

Equity - Common

Series

Seed

Funding Type

RegCF

Price Per Share

$2.05

Pre-Money Valuation

$30,800,000

Rolling Commitments ($USD)

Status

Active

Reporting Date

02/02/2023

Days Remaining

242

% of Min. Goal

23,918%

% of Max. Goal

96%

Likelihood of Max
extremely
Avg. Daily Raise

$39,533

Momentum
warm.svg
Create a free account today to gain access to KingsCrowd analytics.
Location

Wilmington, North Carolina

Industry

Healthcare & Pharmaceuticals

Tech Sector

Medtech

Distribution Model

B2B

Margin

Medium

Capital Intensity

High

Business Type

Growth

Isosceles Pharmaceuticals, with a valuation of $30.8 million, is raising funds on Equifund CFP. It is a pharmaceutical company currently developing intravenous formulations of synthetic Cannabidiol as non-addictive alternatives to opium-based painkillers. The CBD formulations will be used for acute post-operative pain and will address the surgical population in the US, Europe, and the UK. Isosceles Pharmaceuticals is currently in the pre-clinical trials stage. Brett Lanier founded Isosceles Pharmaceuticals in April 2019. The current crowdfunding campaign has a minimum target of $20,000 and a maximum target of $5 million. The campaign proceeds will be used to fund pre-clinical animal trials and IND filings for a new intravenous drug delivery system.

Summary Profit and Loss Statement

Most Recent Year Prior Year

Revenue

$0

$0

COGS

$0

$0

Tax

$0

$0

 

 

Net Income

$879,786

$891,911

Summary Balance Sheet

Most Recent Year Prior Year

Cash

$212,834

$198,240

Accounts Receivable

$0

$0

Total Assets

$212,834

$198,240

Short-Term Debt

$0

$0

Long-Term Debt

$120,000

$0

Total Liabilities

$120,000

$0

Financials as of: 10/04/2022
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$12.42 /month
billed annually
Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings (excluding risk)
Advanced company search ( with ratings)
Markets page filters and historical industry data
Get Edge Annual

Edge Pro

$41.58 /month
billed annually
Full site access including KingsCrowd's qualitative analyst reports.
Plan Includes:
Everything in Edge, plus
Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
Search and filter based on Analyst Reports
In-depth risk ratings for every raise
Get Edge Pro Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Create your first portfolio

Create your very own investment portfolio on KingsCrowd.

Now you can track all of your startup investments in one place utilizing our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
Isosceles Pharmaceuticals on Equifund CFP 2022
$
Platform: Equifund CFP
Security Type: Equity - Common
Valuation: $30,800,000

Follow company

Follow Isosceles Pharmaceuticals on Equifund CFP 2022
View on Equifund CFP